CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

QT Imaging Q3 revenue jumps 75% on scanner sales

By Reuters News


Overview

  • U.S. breast imaging device maker's Q3 revenue rose 75% yr/yr to $7.3 mln

  • Q3 net loss narrowed sharply to $0.3 mln from $4.6 mln a year ago

  • 2026 revenue guidance cut to $34 mln due to Middle East shipment delays


Outlook

  • QT Imaging lowers 2026 revenue guidance to approximately $34 mln from $39 mln

  • Company says international shipment delays due to Middle East conflict impact 2026 outlook

  • Medicare hospital outpatient payment for QTscan exams to begin Jan 1, 2027


Result Drivers

  • SCANNER SALES - Q3 revenue growth driven by higher sales of Breast Acoustic CT scanners, per co

  • MANUFACTURING EXPANSION - Co said relocation to new facility doubled manufacturing capacity and improved efficiency

  • REIMBURSEMENT PROGRESS - CMS decision to establish Medicare hospital outpatient payment for QTscan exams seen as supporting future U.S. hospital expansion


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

$7.34 mln

Q3 Loss Per Basic and Diluted Share

$0.02

Q3 Net Loss

$297,000

Q3 Operating Income

-$2.45 mln

Q3 Pretax Loss

$297,000


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • Wall Street's median 12-month price target for QT Imaging Holdings Inc is $10.00, about 336.7% above its November 9 closing price of $2.29


Reuters Recommended Reads

  • Nov 9 - Hyperfine Q3 revenue jumps on higher system sales; net loss narrows

  • Nov 9 - Ocular Therapeutix Q3 loss widens as product revenue drops, costs rise

  • Nov 10 - LENSAR Q3 revenue slightly misses estimates on slower surgical scheduling


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.